Human renal cell carcinoma expresses distinct binding sites for growth hormone-releasing hormone

Gabor Halmos, Andrew V. Schally, Jozsef L. Varga, Artur Plonowski, Z. Rékási, T. Czömpöly

Research output: Contribution to journalArticle

77 Citations (Scopus)

Abstract

Antagonists of growth hormone-releasing hormone (GHRH) inhibit the proliferation of various human cancers in vitro and in vivo by mechanisms that include apparent direct effects through specific binding sites expressed on tumors and that differ from pituitary human GHRH (hGHRH) receptors. In this study, GHRH antagonist JV-1-38 (20 μg/day per animal s.c.) inhibited the growth of orthotopic CAKI-1 human renal cell carcinoma (RCC) by 83% and inhibited the development of metastases to lung and lymph nodes. Using ligand competition assays with 125I-labeled GHRH antagonist JV-1-42, we demonstrated the presence of specific high-affinity (K(d) = 0.25 ± 0.03 nM) binding sites for GHRH with a maximal binding capacity (B(max)) of 70.2 ± 4.1 fmol/mg of membrane protein in CAKI-1 tumors. These receptors bind GHRH antagonists preferentially and display a lower affinity for hGHRH. The binding of 125I-JV-1-42 is not inhibited by vasoactive intestinal peptide (VIP)-related peptides sharing structural homology with hGHRH. The receptors for GHRH antagonists on CAKI-1 tumors are distinct from binding sites detected with 125I-VIP (K(d) = 0.89 ± 0.14 nM; B(max) = 183.5 ± 2.6 fmol/mg of protein) and also have different characteristics from GHRH receptors on rat pituitary as documented by the insignificant binding of [His 1,125I-Tyr10,Nle27]hGHRH(1-32)NH2. Reverse transcription-PCR revealed the expression of splice variants of hGHRH receptor in CAKI-1 RCC. Biodistribution studies demonstrate an in vivo uptake of 125I-JV-1-42 by the RCC tumor tissue. The presence of specific receptor proteins that bind GHRH antagonists in CAKI-1 RCC supports the view that distinct binding sites that mediate the inhibitory effect of GHRH antagonists are present on various human cancers.

Original languageEnglish
Pages (from-to)10555-10560
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume97
Issue number19
Publication statusPublished - Sep 12 2000

Fingerprint

Growth Hormone-Releasing Hormone
Hormone Antagonists
Renal Cell Carcinoma
Binding Sites
Somatotropin Receptors
Neoplasms
Vasoactive Intestinal Peptide
Human Growth Hormone
Growth Hormone
Reverse Transcription
Membrane Proteins
Proteins
Lymph Nodes
Neoplasm Metastasis
Ligands
Polymerase Chain Reaction
Lung
Peptides
Renal cell carcinoma 1
Growth

Keywords

  • Growth hormone-releasing hormone antagonists
  • Tumor receptors

ASJC Scopus subject areas

  • Genetics
  • General

Cite this

Human renal cell carcinoma expresses distinct binding sites for growth hormone-releasing hormone. / Halmos, Gabor; Schally, Andrew V.; Varga, Jozsef L.; Plonowski, Artur; Rékási, Z.; Czömpöly, T.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 97, No. 19, 12.09.2000, p. 10555-10560.

Research output: Contribution to journalArticle

@article{55ec98e3c71642faa392b1658ed054d3,
title = "Human renal cell carcinoma expresses distinct binding sites for growth hormone-releasing hormone",
abstract = "Antagonists of growth hormone-releasing hormone (GHRH) inhibit the proliferation of various human cancers in vitro and in vivo by mechanisms that include apparent direct effects through specific binding sites expressed on tumors and that differ from pituitary human GHRH (hGHRH) receptors. In this study, GHRH antagonist JV-1-38 (20 μg/day per animal s.c.) inhibited the growth of orthotopic CAKI-1 human renal cell carcinoma (RCC) by 83{\%} and inhibited the development of metastases to lung and lymph nodes. Using ligand competition assays with 125I-labeled GHRH antagonist JV-1-42, we demonstrated the presence of specific high-affinity (K(d) = 0.25 ± 0.03 nM) binding sites for GHRH with a maximal binding capacity (B(max)) of 70.2 ± 4.1 fmol/mg of membrane protein in CAKI-1 tumors. These receptors bind GHRH antagonists preferentially and display a lower affinity for hGHRH. The binding of 125I-JV-1-42 is not inhibited by vasoactive intestinal peptide (VIP)-related peptides sharing structural homology with hGHRH. The receptors for GHRH antagonists on CAKI-1 tumors are distinct from binding sites detected with 125I-VIP (K(d) = 0.89 ± 0.14 nM; B(max) = 183.5 ± 2.6 fmol/mg of protein) and also have different characteristics from GHRH receptors on rat pituitary as documented by the insignificant binding of [His 1,125I-Tyr10,Nle27]hGHRH(1-32)NH2. Reverse transcription-PCR revealed the expression of splice variants of hGHRH receptor in CAKI-1 RCC. Biodistribution studies demonstrate an in vivo uptake of 125I-JV-1-42 by the RCC tumor tissue. The presence of specific receptor proteins that bind GHRH antagonists in CAKI-1 RCC supports the view that distinct binding sites that mediate the inhibitory effect of GHRH antagonists are present on various human cancers.",
keywords = "Growth hormone-releasing hormone antagonists, Tumor receptors",
author = "Gabor Halmos and Schally, {Andrew V.} and Varga, {Jozsef L.} and Artur Plonowski and Z. R{\'e}k{\'a}si and T. Cz{\"o}mp{\"o}ly",
year = "2000",
month = "9",
day = "12",
language = "English",
volume = "97",
pages = "10555--10560",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "19",

}

TY - JOUR

T1 - Human renal cell carcinoma expresses distinct binding sites for growth hormone-releasing hormone

AU - Halmos, Gabor

AU - Schally, Andrew V.

AU - Varga, Jozsef L.

AU - Plonowski, Artur

AU - Rékási, Z.

AU - Czömpöly, T.

PY - 2000/9/12

Y1 - 2000/9/12

N2 - Antagonists of growth hormone-releasing hormone (GHRH) inhibit the proliferation of various human cancers in vitro and in vivo by mechanisms that include apparent direct effects through specific binding sites expressed on tumors and that differ from pituitary human GHRH (hGHRH) receptors. In this study, GHRH antagonist JV-1-38 (20 μg/day per animal s.c.) inhibited the growth of orthotopic CAKI-1 human renal cell carcinoma (RCC) by 83% and inhibited the development of metastases to lung and lymph nodes. Using ligand competition assays with 125I-labeled GHRH antagonist JV-1-42, we demonstrated the presence of specific high-affinity (K(d) = 0.25 ± 0.03 nM) binding sites for GHRH with a maximal binding capacity (B(max)) of 70.2 ± 4.1 fmol/mg of membrane protein in CAKI-1 tumors. These receptors bind GHRH antagonists preferentially and display a lower affinity for hGHRH. The binding of 125I-JV-1-42 is not inhibited by vasoactive intestinal peptide (VIP)-related peptides sharing structural homology with hGHRH. The receptors for GHRH antagonists on CAKI-1 tumors are distinct from binding sites detected with 125I-VIP (K(d) = 0.89 ± 0.14 nM; B(max) = 183.5 ± 2.6 fmol/mg of protein) and also have different characteristics from GHRH receptors on rat pituitary as documented by the insignificant binding of [His 1,125I-Tyr10,Nle27]hGHRH(1-32)NH2. Reverse transcription-PCR revealed the expression of splice variants of hGHRH receptor in CAKI-1 RCC. Biodistribution studies demonstrate an in vivo uptake of 125I-JV-1-42 by the RCC tumor tissue. The presence of specific receptor proteins that bind GHRH antagonists in CAKI-1 RCC supports the view that distinct binding sites that mediate the inhibitory effect of GHRH antagonists are present on various human cancers.

AB - Antagonists of growth hormone-releasing hormone (GHRH) inhibit the proliferation of various human cancers in vitro and in vivo by mechanisms that include apparent direct effects through specific binding sites expressed on tumors and that differ from pituitary human GHRH (hGHRH) receptors. In this study, GHRH antagonist JV-1-38 (20 μg/day per animal s.c.) inhibited the growth of orthotopic CAKI-1 human renal cell carcinoma (RCC) by 83% and inhibited the development of metastases to lung and lymph nodes. Using ligand competition assays with 125I-labeled GHRH antagonist JV-1-42, we demonstrated the presence of specific high-affinity (K(d) = 0.25 ± 0.03 nM) binding sites for GHRH with a maximal binding capacity (B(max)) of 70.2 ± 4.1 fmol/mg of membrane protein in CAKI-1 tumors. These receptors bind GHRH antagonists preferentially and display a lower affinity for hGHRH. The binding of 125I-JV-1-42 is not inhibited by vasoactive intestinal peptide (VIP)-related peptides sharing structural homology with hGHRH. The receptors for GHRH antagonists on CAKI-1 tumors are distinct from binding sites detected with 125I-VIP (K(d) = 0.89 ± 0.14 nM; B(max) = 183.5 ± 2.6 fmol/mg of protein) and also have different characteristics from GHRH receptors on rat pituitary as documented by the insignificant binding of [His 1,125I-Tyr10,Nle27]hGHRH(1-32)NH2. Reverse transcription-PCR revealed the expression of splice variants of hGHRH receptor in CAKI-1 RCC. Biodistribution studies demonstrate an in vivo uptake of 125I-JV-1-42 by the RCC tumor tissue. The presence of specific receptor proteins that bind GHRH antagonists in CAKI-1 RCC supports the view that distinct binding sites that mediate the inhibitory effect of GHRH antagonists are present on various human cancers.

KW - Growth hormone-releasing hormone antagonists

KW - Tumor receptors

UR - http://www.scopus.com/inward/record.url?scp=0034641699&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034641699&partnerID=8YFLogxK

M3 - Article

VL - 97

SP - 10555

EP - 10560

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 19

ER -